Mozavaptan
Encyclopedia
Mozavaptan is a vasopressin receptor antagonist
marketed by Otsuka
. In Japan, it was approved in October 2006 for hyponatremia
(low blood sodium
levels) caused by syndrome of inappropriate antidiuretic hormone
(SIADH) due to ADH producing tumors.
Vasopressin receptor antagonist
A vasopressin receptor antagonist is an agent which interferes with action at the vasopressin receptors. They can be used in the treatment of hyponatremia, especially in patients with congestive heart failure or liver cirrhosis.-Tetracyclines:...
marketed by Otsuka
Otsuka Pharmaceutical Co.
, abbreviated OPC, is a pharmaceutical company headquartered in Tokyo, Osaka and Naruto, Japan. The company was established August 10, 1964, and currently has approximately 27,000 employees worldwide. The company focuses on pharmaceuticals related to nutrition...
. In Japan, it was approved in October 2006 for hyponatremia
Hyponatremia
Hyponatremia is an electrolyte disturbance in which the sodium concentration in the serum is lower than normal. In the vast majority of cases, hyponatremia occurs as a result of excess body water diluting the serum sodium and is not due to sodium deficiency. Sodium is the dominant extracellular...
(low blood sodium
Sodium
Sodium is a chemical element with the symbol Na and atomic number 11. It is a soft, silvery-white, highly reactive metal and is a member of the alkali metals; its only stable isotope is 23Na. It is an abundant element that exists in numerous minerals, most commonly as sodium chloride...
levels) caused by syndrome of inappropriate antidiuretic hormone
Syndrome of inappropriate antidiuretic hormone
The syndrome of inappropriate antidiuretic hormone hypersecretion is characterized by excessive release of antidiuretic hormone from the posterior pituitary gland or another source. The result is hyponatremia and sometimes fluid overload...
(SIADH) due to ADH producing tumors.